The biotech's growth portfolio continues to add to its overall top line.

Leqembi, which was approved in 2023 to treat the mind-robbing disease, generated $168 million in sales, up 74 percent from ...

Biogen first-quarter profit and revenue rose, buoyed by rising sales from its growth products, led by its drug to treat early ...

Biogen (NASDAQ:BIIB) executives pointed to a “very strong start” to 2026, highlighting growth in key products, progress ...

Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...

Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...

Biogen has entered into an agreement with TJ Biopharma (TJ Bio) to acquire exclusive rights to felzartamab in the Greater ...

On Apellis, "we have the proposed Apellis acquisition" and "we do expect the acquisition to be accretive in 2027" (CEO Viehbacher). "Total revenue was $2.5 billion" and "non-GAAP diluted EPS of $3.57" ...

Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the ...

Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.

Biogen has agreed to acquire ​Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines.

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.